KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 156 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 4.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $834,625 | -22.0% | 622,855 | +4.2% | 0.00% | 0.0% |
| Q2 2023 | $1,069,989 | -50.0% | 597,759 | +8.8% | 0.00% | -50.0% |
| Q1 2023 | $2,137,971 | +104.2% | 549,607 | +78.5% | 0.00% | +100.0% |
| Q4 2022 | $1,047,061 | +33.4% | 307,959 | +114.1% | 0.00% | 0.0% |
| Q3 2022 | $785,000 | +197.3% | 143,806 | +145.8% | 0.00% | – |
| Q2 2022 | $264,000 | +5.2% | 58,500 | +71.5% | 0.00% | – |
| Q1 2022 | $251,000 | -77.8% | 34,113 | -80.6% | 0.00% | -100.0% |
| Q4 2021 | $1,132,000 | +625.6% | 176,051 | +1084.3% | 0.00% | – |
| Q1 2021 | $156,000 | -99.3% | 14,865 | -98.9% | 0.00% | -100.0% |
| Q4 2020 | $21,396,000 | -38.6% | 1,382,133 | -42.1% | 0.02% | -47.2% |
| Q3 2020 | $34,857,000 | -38.1% | 2,387,470 | -19.7% | 0.04% | -46.3% |
| Q2 2020 | $56,347,000 | +22.0% | 2,975,015 | +23.8% | 0.07% | -6.9% |
| Q1 2020 | $46,177,000 | +1.8% | 2,403,780 | +1.6% | 0.07% | +38.5% |
| Q4 2019 | $45,346,000 | +241.3% | 2,365,511 | +71.3% | 0.05% | +225.0% |
| Q3 2019 | $13,285,000 | +175.4% | 1,381,027 | +71.5% | 0.02% | +166.7% |
| Q2 2019 | $4,824,000 | +85.1% | 805,462 | +80.4% | 0.01% | +100.0% |
| Q1 2019 | $2,606,000 | +63.9% | 446,375 | +163.1% | 0.00% | +50.0% |
| Q4 2018 | $1,590,000 | -58.2% | 169,668 | -24.0% | 0.00% | -60.0% |
| Q3 2018 | $3,802,000 | +30.5% | 223,263 | +30.2% | 0.01% | +25.0% |
| Q2 2018 | $2,914,000 | +23.7% | 171,512 | -2.3% | 0.00% | +33.3% |
| Q1 2018 | $2,356,000 | +237.1% | 175,541 | +141.2% | 0.00% | +200.0% |
| Q4 2017 | $699,000 | +5.1% | 72,771 | +20.2% | 0.00% | 0.0% |
| Q3 2017 | $665,000 | -1.6% | 60,549 | -18.9% | 0.00% | 0.0% |
| Q2 2017 | $676,000 | -63.9% | 74,673 | -48.8% | 0.00% | -66.7% |
| Q1 2017 | $1,872,000 | +383.7% | 145,765 | +253.2% | 0.00% | +200.0% |
| Q4 2016 | $387,000 | +40.7% | 41,270 | +46.2% | 0.00% | – |
| Q3 2016 | $275,000 | -56.5% | 28,219 | -40.8% | 0.00% | -100.0% |
| Q4 2015 | $632,000 | +23.2% | 47,700 | -2.1% | 0.00% | 0.0% |
| Q3 2015 | $513,000 | – | 48,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |